Unlock instant, AI-driven research and patent intelligence for your innovation.

Modified hepatitis C virus (HCV) Type 5 envelope E2 protein and application thereof

A hepatitis C virus, hepatitis C technology, applied in applications, viral peptides, antiviral agents, etc.

Inactive Publication Date: 2015-01-14
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

HVR1 antibody can efficiently neutralize HCV infection in vitro, but the neutralization effect of HVR1 antibody has strict strain specificity, that is, the antibody against a certain strain of HCV HVR1 can only neutralize the infection of the same strain of HCV, but not the infection of other strains of HCV. No neutralization

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified hepatitis C virus (HCV) Type 5 envelope E2 protein and application thereof
  • Modified hepatitis C virus (HCV) Type 5 envelope E2 protein and application thereof
  • Modified hepatitis C virus (HCV) Type 5 envelope E2 protein and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Example 1: Amplification of the 1-6 genotype HCV envelope E2 protein gene containing HVR1 and deleting HVR1:

[0049] HCV envelope protein E1E2 genes of types 1a, 1b, and 2a were donated by Professor C.M.Rice of Rockefeller University in the United States; HCV envelope protein E1E2 genes of types 3a, 4, 5, and 6 were donated by Professor J.K.Ball of Nottingham University in the United Kingdom. See Table 1 for the gene sequence. Design and synthesize primers according to the corresponding sequences of 7 HCV envelope E2 genes of 1-6 genotypes (1a, 1b, 2a, 3a, 4, 5, 6), and amplify E2 protein by polymerase chain reaction (PCR) Extracellular segment gene (equivalent to 364-661 amino acid residues of HCV polyprotein, 364-383 amino acid residues as secretory signal peptide of E2 protein). The sequences of amplification primers (upstream primer FP1 and downstream primer RP) are shown in Table 2. Reagents for PCR amplification are products of Promega Corporation, USA.

[005...

Embodiment 2

[0058] Embodiment 2: Identification of 1-6 genotype HCV envelope E2 protein expression product:

[0059] Human embryonic kidney (HEK) 293T cells were subcultured in DMEM medium containing 10% fetal bovine serum. When the cells were 80% confluent, the cells were digested with 0.25% trypsin, subcultured and inoculated on 35mm cell culture dishes, and cultured overnight. Combine 4 μg of plasmids constructed above with 7 strains of HCV envelope E2 protein expression plasmids pCI-E2t (including HVR1), pCI-E2tΔ (deleted HVR1) and empty vector pCI-neo with 10 μl of transfection reagent lipid Plastid Lipofectamine (product of Invitrogen, USA) was mixed and transfected into HEK293T cells, and the operation was performed according to the instructions. After adding the plasmid-liposome mixture to the cell culture dish, place the cell culture dish in a cell culture incubator at 37°C, 5% carbon dioxide, and saturated humidity, and add 1ml of complete DMEM culture solution containing 10% fe...

Embodiment 3

[0061] Embodiment 3: Mouse gene immunization and antibody detection:

[0062] Use a plasmid extraction kit (product of Qiagen, Germany) to prepare and purify a large number of HCV envelope E2 protein expression plasmids pCI-E2t, pCI-E2tΔ and empty vector pCI-neo of the above 1-6 genotypes, and dissolve them in PBS buffer (pH 7.4), adjust the concentration to 100μg / ml, immunize Balb / C mice, immunize 10 mice with each plasmid, inject 0.1ml of the plasmid solution into the tibialis anterior muscle on each side, and the equivalent dose is 20μg of the plasmid per mouse. A total of three immunizations were performed with an interval of two weeks. The day before each immunization (0, 2, 4 weeks respectively, the first blood collection time was set as 0 weeks) and every two weeks after the last immunization (7 times in total, the time was 6, 8, 10, 12, 14, 16 and 18 weeks) Blood was collected from the orbit of the mice, and E2t (including HVR1), E2tΔ (deleted HVR1) and HVR1 antibodie...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of biomedicine engineering. The invention provides a modified hepatitis C virus (HCV) Type 5 envelope E2 protein and application thereof in hepatitis C vaccines and HCV infection immunodiagnosis reagents. The animal immunity test detects that HVR1 (hypervariable region 1) in the HCV Type 5 envelope E2 protein has an obvious inhibiting action on immunogenicity of conserved neutralizing epitope in the envelope protein E2; and the deletion of the HVR1 can obviously enhance the efficacy of the E2 protein for inducing broad-spectrum neutralizing antibody, i.e. the HCV envelope E2 protein without the HVR1 is probably used as an effective hepatitis C vaccine target antigen. The invention also proves that the reaction between the HCV envelope E2 protein without the HVR1 and the E2 antibody in the serum of an HCV infected person is obviously strengthened, and thus, the HCV envelope E2 protein without the HVR1 can be used as an HCV infection immunodiagnosis antigen.

Description

[0001] This application is a divisional application of the patent application No. 201110057284.4 submitted on March 10, 2011, and the title of the invention is "HCV envelope E2 protein with hypervariable region 1 deleted and its use". technical field [0002] The invention relates to the technical field of biomedical engineering, and relates to a hepatitis C virus (HCV) envelope E2 protein with hypervariable region 1 deleted and its application in hepatitis C vaccine and immunodiagnostic reagents for HCV infection . Background technique [0003] Hepatitis C virus (HCV) belongs to the Flaviviridae family and is one of the main pathogenic factors of acute and chronic hepatitis transmitted by blood. HCV is a single-stranded positive-sense RNA virus with only one open reading frame, encoding a protein precursor of about 3010 amino acids, including three structural proteins (core protein Core, envelope protein E1, envelope protein E2) and seven non- Structural proteins (p7 prote...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/18C12N15/51A61K39/29A61K48/00A61P31/14G01N33/68G01N33/569C12R1/93
Inventor 赵平戚中田
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY